Axsome Therapeutics, Inc. (NASDAQ:AXSM) Holdings Boosted by Brevan Howard Capital Management LP

Brevan Howard Capital Management LP grew its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 169.9% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,748 shares of the company's stock after acquiring an additional 24,393 shares during the quarter. Brevan Howard Capital Management LP owned about 0.08% of Axsome Therapeutics worth $3,278,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. JPMorgan Chase & Co. increased its position in shares of Axsome Therapeutics by 14.9% during the 3rd quarter. JPMorgan Chase & Co. now owns 212,110 shares of the company's stock worth $19,062,000 after purchasing an additional 27,534 shares during the last quarter. Strategic Financial Concepts LLC purchased a new stake in shares of Axsome Therapeutics in the 4th quarter valued at approximately $2,599,000. Intech Investment Management LLC lifted its holdings in shares of Axsome Therapeutics by 46.5% in the 4th quarter. Intech Investment Management LLC now owns 16,028 shares of the company's stock worth $1,356,000 after acquiring an additional 5,087 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Axsome Therapeutics during the 4th quarter worth approximately $14,771,000. Finally, Charles Schwab Investment Management Inc. increased its holdings in Axsome Therapeutics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 328,034 shares of the company's stock valued at $27,755,000 after purchasing an additional 5,438 shares during the last quarter. 81.49% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on AXSM. Leerink Partners lifted their target price on Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a research report on Monday, February 10th. Morgan Stanley increased their target price on Axsome Therapeutics from $125.00 to $190.00 and gave the company an "overweight" rating in a report on Thursday, February 27th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $153.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, February 19th. Mizuho boosted their target price on Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research note on Thursday, March 27th. Finally, HC Wainwright dropped their price target on shares of Axsome Therapeutics from $200.00 to $180.00 and set a "buy" rating on the stock in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $172.14.

Insider Transactions at Axsome Therapeutics

In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total value of $393,210.00. Following the completion of the sale, the chief financial officer now directly owns 42,187 shares in the company, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Trading Down 1.0 %

NASDAQ AXSM traded down $1.10 during trading hours on Friday, hitting $107.76. 435,267 shares of the company's stock were exchanged, compared to its average volume of 682,708. The business's 50 day moving average is $112.01 and its 200-day moving average is $104.59. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The firm has a market capitalization of $5.31 billion, a P/E ratio of -17.99 and a beta of 0.46.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million during the quarter, compared to analyst estimates of $117.83 million. As a group, analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.